Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Personalis, Inc. before investing.

In this article, we go over a few key elements for understanding Personalis, Inc.’s stock price such as:

• Personalis, Inc.’s current stock price and volume
• Why Personalis, Inc.’s stock price changed recently
• Upgrades and downgrades for PSNL from analysts
• PSNL’s stock price momentum as measured by its relative strength

About Personalis, Inc. (PSNL)

Before we jump into Personalis, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company’s customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Want to learn more about Personalis, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Personalis, Inc..

Personalis, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Personalis, Inc.’s stock price was $12.660.

Personalis, Inc. is up 3.09% from its previous closing price of $12.280.

During the last market session, Personalis, Inc.’s stock traded between $12.300 and $12.870. Currently, there are approximately 104.19 million shares outstanding for Personalis, Inc..

Personalis, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Personalis, Inc. Stock Price History

Personalis, Inc.’s (PSNL) price is currently down 5.52% so far this month.

During the month of July, Personalis, Inc.’s stock price has reached a high of $16.390 and a low of $11.520.

Over the last year, Personalis, Inc. has hit prices as high as $16.390 and as low as $3.840. Year to date, Personalis, Inc.’s stock is up 59.05%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Personalis, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Personalis, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Personalis, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Personalis, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Personalis, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Personalis, Inc. (PSNL) by visiting AAII Stock Evaluator.

Relative Price Strength of Personalis, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Personalis, Inc. has a weighted four-quarter relative price strength of 47.92%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Personalis, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Personalis, Inc. Stock Price: Bottom Line

As of July 31, 2026, Personalis, Inc.’s stock price is $12.660, which is up 3.09% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Personalis, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.